A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-01-11
AEs
3
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 43); relationship: Y
severe
serious
assessed
Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-12 (study day 315); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-06-12 (study day 498); relationship: not assessed
Data queries
No data queries.